BOSTON ( TheStreet) -- Welcome to August's Biotech Stock Mailbag Live Chat. The floor is yours. I'm here for the next 90 minutes or so to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below. Dendreon's ( DNDN) blow up is certainly the biggest biotech story of the past month, so let's hash out the company's future and what needs to happen for the stock to recover. I'm happy to discuss Amarin ( AMRN) and the controversy over the patents for its lead drug AMR101. The biotech sector's most-followed stock indices are down for the year, following the broader market selloff, but there are good biotech stocks to be found in a bear market. I recently discussed a few of these -- Celgene ( CELG), Biogen Idec ( BIIB), Elan ( ELN), Alexion Pharmaceuticals ( ALXN). Feel free to disagree or highlight other biotech stocks you think investors should take a look at in this shaky market. Seattle Genetics ( SGEN), Nupathe ( PATH), Pacira Pharmaceuticals ( PCRX), Spectrum Pharmaceuticals ( SPPI) and Incyte ( INCY) are among the companies with looming FDA drug approval decisions. Then there's biotech stocks with big clinical trial catalysts on the way: Oncothyreon ( ONTY), Celsion ( CLSN), Keryx Pharmaceuticals ( KERX). Let's talk about all these stocks today, or any other biotech investing subjects that pique your interest. Please join me live. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.